Hsa_circ_0007841: A Novel Potential Biomarker and Drug Resistance for Multiple Myeloma

Frontiers in Oncology - Switzerland
doi 10.3389/fonc.2019.01261
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA

Related search

Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma

BioMed Research International
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2015English

Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance

Cancer Research
Cancer ResearchOncology
2008English

Old and Young Actors Playing Novel Roles in the Drama of Multiple Myeloma Bone Marrow Microenvironment Dependent Drug Resistance

International Journal of Molecular Sciences
Organic ChemistryMolecular BiologyTheoretical ChemistryInorganic ChemistryComputer Science ApplicationsSpectroscopyMedicineCatalysisPhysical
2018English

Targeting the Fanconi Anemia/Brca Pathway Circumvents Drug Resistance in Multiple Myeloma

Cancer Research
Cancer ResearchOncology
2009English

Multiple Myeloma Exploits Jagged1 and Jagged2 to Promote Intrinsic and Bone Marrow-Dependent Drug Resistance

Haematologica
Hematology
2019English

MiR-30a: A Novel Biomarker and Potential Therapeutic Target for Cancer

Journal of Oncology
Oncology
2018English

Novel Drugs for the Treatment of Multiple Myeloma

Haematologica
Hematology
2010English

CHIR-258, a Novel, Multitargeted Tyrosine Kinase Inhibitor for the Potential Treatment of T(4;14) Multiple Myeloma

Blood
BiochemistryImmunologyCell BiologyHematology
2005English

TRAIL/Apo2L Ligand Selectively Induces Apoptosis and Overcomes Drug Resistance in Multiple Myeloma: Therapeutic Applications

Blood
BiochemistryImmunologyCell BiologyHematology
2001English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy